Payload– tag –
-
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat... -
SpaceX Starship Successfully Deploys Next-Gen Starlink V3 Satellites, Captures Orbital Footage of Upper Stage on 13th Test Flight
Space.com USA Overview SpaceX's Starship completed its 13th test flight on July 24, successfully deploying next-generation Starlink internet satellites into orbit for the first time. During this mission, six "Starlink V3" satellites capt... -
Rocket Lab, with $1.1B+ Backlog and 50+ Electron Launches, Targets 2026 Neutron Debut to Capture Falcon 9 Market Segment
TradingKey USA Overview Rocket Lab is aggressively expanding its small satellite launch services and space systems manufacturing, underpinned by over 50 successful Electron launches and a robust $1.1 billion+ backlog. Its reusable medium... -
LNP-Delivered Gene Editing Platform Targets Hepatic Lipid Metabolic Disorders for Durable, Single-Intervention Correction
Ace Therapeutics USA Overview This platform focuses on lipid nanoparticle (LNP)-delivered gene editing for heritable lipid disorders, aiming for durable, single-intervention correction of disease-driving genes in the liver. It integrates... -
Pathos AI Licenses Alphamab’s First-in-Class TROP2/HER3 Bispecific ADC JSKN016 in $2.25 Billion Deal to Advance Breast Cancer Treatment
Fierce Biotech USA Overview Pathos AI has licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) from Alphamab, in a deal worth up to $2.25 billion ($125 million upfront, $2.1 billion in milestones). JSKN0... -
Asia-Pacific AI Drug Discovery Platforms Mature, Achieving Key Clinical Milestones
BioPharma APAC Asia-Pacific Overview AI drug discovery platforms in the Asia-Pacific region are demonstrating significant clinical traction, with Hummingbird Bioscience initiating patient dosing for its HER3-targeted ADC and Insilico Med... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
CREATE Medicines Expands Targeted In Vivo CAR Platform via Monash University Partnership, Driving Cell-Type-Specific Delivery with Advanced LNP Technology
BioSpace Australia Overview CREATE Medicines has expanded its targeted in vivo CAR platform through a strategic research collaboration and exclusive license agreement with Monash University. This partnership leverages targeted lipid nano... -
Kepler Communications Expands On-Orbit Computing and Data Relay Services in Europe, Recruiting European Sales Director
Arbeitnow Canada Overview Kepler Communications, a leader in real-time on-orbit connectivity, is accelerating its European expansion by recruiting a Sales Director for the region. The company currently operates 33 satellites, forming the... -
China Successfully Completes World’s First On-Orbit Test of 400V Space Power System on Tianzhou-10
Global Times China Overview China successfully completed all on-orbit tests of its new-generation space power system aboard the Tianzhou-10 cargo spacecraft, marking the world's first application of a 400V bus power system in orbit. This...
